Table 2. . Persistence in the use of anti-TNF and conventional synthetic disease-modifying antirheumatic drug medications in individuals with psoriatic arthritis.
| Medicine | % persistent 6 months | % persistent 12 months | Average in days 6 months (95% CI) | Average in days 12 months (95% CI) |
|---|---|---|---|---|
| Anti-TNF | 83.4 | 66.4 | 166.5 (159.6–173.3) | 297.3 (278.0–316.5) |
| Adalimumab | 86.5 | 69.7 | 170.4 (162.9–178.0) | 306.1 (282.4–329.9) |
| Etanercept | 84.4 | 69.0 | 168.5 (157.2–179.8) | 306.9 (274.6–339.1) |
| Infliximab | 64.7 | 43.8 | 140.4 (106.4–174.3) | 229.9 (156.9–303.0) |
| csDMARD | 50.8 | 35.6 | 135.5 (120.3–150.7) | 207.2 (171.7–242.7) |
| Leflunomide | 51.7 | 37.0 | 139.1 (116.5–161.7) | 209.9 (157.8–262.0) |
| Methotrexate | 50.0 | 34.4 | 132.4 (111.6–153.2) | 204.9 (155.6–254.2) |
csDMARD: Conventional synthetic disease-modifying antirheumatic drug.